Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

Clinical trial NCT06348134 · RECRUITING

Trial details

NCT number: NCT06348134
Sponsor: University of Chicago
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Human Epidermal Growth Factor 2 Negative Carcinoma of Breast HER2-positive Breast Cancer Breast Cancer

Start date: 2025-03-18
Primary completion: 2034-07-01
Enrollment: 74

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.